Paeoniflorin ameliorates ulcerative colitis by modulating the dendritic cell-mediated T H 17/T reg balance

  • PDF / 7,104,231 Bytes
  • 12 Pages / 595.276 x 790.866 pts Page_size
  • 10 Downloads / 190 Views

DOWNLOAD

REPORT


Inflammopharmacology

ORIGINAL ARTICLE

Paeoniflorin ameliorates ulcerative colitis by modulating the dendritic cell‑mediated ­TH17/Treg balance Kai Zheng1   · Jia Jia2 · Shihai Yan3 · Hong Shen1 · Ping Zhu4 · Jiangyi Yu2 Received: 17 November 2019 / Accepted: 11 May 2020 © The Author(s) 2020

Abstract Immunological tolerance is critical for maintaining gut homeostasis. An imbalance between interleukin-17 (IL-17)-producing T helper 17 ­(TH17) cells and regulatory T cells ­(Treg cells) is involved in ulcerative colitis (UC) pathogenesis. Dendritic cells (DCs) are able to induce T cell differentiation. Paeoniflorin (PF) is a monoterpene glucoside that is commonly used for treatment of autoimmune disease. However, the immunological mechanism of PF involvement in UC treatment is unclear. The present study aimed to explore whether PF can restore the ­TH17/Treg balance by modulating DCs. The effects of PF on DCs, ­TH17 cells and ­Treg cells were measured. Furthermore, PF-treated DCs were injected into mice with 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis. PF inhibited MHC-II and CD86 expression on the DC surface (P